Morgan Stanley
MLYS icon

Morgan Stanley’s Mineralys Therapeutics MLYS Stock Holding History

Morgan Stanley’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.7M Buy
917,213
+68,029
+8% +$1.87M ﹤0.01% 2907
2026
Q1 		$23M Buy
849,184
+209,677
+33% +$6.15M ﹤0.01% 2826
2025
Q4 		$23.2M Sell
639,507
-737,491
-54% -$29.6M ﹤0.01% 2789
2025
Q3 		$52.2M Buy
1,376,998
+789,168
+134% +$17.1M ﹤0.01% 1973
2025
Q2 		$7.95M Sell
587,830
-31,918
-5% -$463K ﹤0.01% 3656
2025
Q1 		$9.84M Buy
619,748
+30,304
+5% +$349K ﹤0.01% 3353
2024
Q4 		$7.26M Buy
589,444
+73,631
+14% +$963K ﹤0.01% 3666
2024
Q3 		$6.25M Buy
515,813
+44,289
+9% +$536K ﹤0.01% 3799
2024
Q2 		$5.52M Sell
471,524
-50,485
-10% -$636K ﹤0.01% 3795
2024
Q1 		$6.74M Sell
522,009
-549,027
-51% -$6.78M ﹤0.01% 3666
2023
Q4 		$9.21M Buy
1,071,036
+936,364
+695% +$7.35M ﹤0.01% 3987
2023
Q3 		$1.28M Buy
134,672
+84,507
+168% +$1.1M ﹤0.01% 4649
2023
Q2 		$855K Buy
50,165
+20,114
+67% +$301K ﹤0.01% 4924
2023
Q1 		$471K Buy
+30,051
New +$506K ﹤0.01% 5290

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley's MLYS Position: Q2 2026 in Review

Morgan Stanley increased its Mineralys Therapeutics (MLYS) stake by 8% in Q2 2026, buying an estimated $1.87M and bringing the position to 917,213 shares worth $24.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2907.

Morgan Stanley first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. The position peaked at $52.2M in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Morgan Stanley held 917,213 shares of Mineralys Therapeutics worth $24.7M as of Q2 2026.
  • Morgan Stanley bought 68,029 Mineralys Therapeutics shares in Q2 2026, an estimated $1.87M.
  • Mineralys Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2907 holding.
  • Morgan Stanley first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Morgan Stanley's Mineralys Therapeutics position peaked at $52.2M in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.